- Home
- IPHA vs ENTA Comparison
IPHA vs ENTA Comparison
Compare IPHA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- ENTA
- Stock Information
- Founded
- IPHA 1999
- ENTA 1995
- Country
- IPHA France
- ENTA United States
- Employees
- IPHA N/A
- ENTA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- ENTA Health Care
- Exchange
- IPHA Nasdaq
- ENTA Nasdaq
- Market Cap
- IPHA 160.1M
- ENTA 164.6M
- IPO Year
- IPHA 2019
- ENTA 2013
- Fundamental
- Price
- IPHA $1.95
- ENTA $11.08
- Analyst Decision
- IPHA Hold
- ENTA Strong Buy
- Analyst Count
- IPHA 2
- ENTA 6
- Target Price
- IPHA $2.00
- ENTA $20.83
- AVG Volume (30 Days)
- IPHA 21.4K
- ENTA 1.5M
- Earning Date
- IPHA 09-17-2025
- ENTA 11-24-2025
- Dividend Yield
- IPHA N/A
- ENTA N/A
- EPS Growth
- IPHA N/A
- ENTA N/A
- EPS
- IPHA N/A
- ENTA N/A
- Revenue
- IPHA $14,839,695.00
- ENTA $64,806,000.00
- Revenue This Year
- IPHA $350.96
- ENTA N/A
- Revenue Next Year
- IPHA $32.92
- ENTA $1.65
- P/E Ratio
- IPHA N/A
- ENTA N/A
- Revenue Growth
- IPHA N/A
- ENTA N/A
- 52 Week Low
- IPHA $1.29
- ENTA $4.09
- 52 Week High
- IPHA $3.51
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- IPHA 50.85
- ENTA 57.90
- Support Level
- IPHA $1.95
- ENTA $9.91
- Resistance Level
- IPHA $2.10
- ENTA $11.59
- Average True Range (ATR)
- IPHA 0.07
- ENTA 1.50
- MACD
- IPHA 0.02
- ENTA 0.24
- Stochastic Oscillator
- IPHA 66.09
- ENTA 48.61
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.